Tens of thousands of patients have withdrawn their personal medical data from research projects amid mounting public mistrust of Palantir, according to new government figures. Health innovation minister James Frith stated in a letter to Commons health committee chair Layla Moran that 60,000 additional people opted out of sharing their private information between mid-May and mid-July, raising urgent questions over the future of the American health tech firm’s £330m contract with the National Health Service.
Palantir NHS Contract Faces Scrutiny Amid Rising Data Opt-Outs
Ministers are currently weighing whether to terminate the firm’s £330m agreement to manage the health service’s federated data platform, a system designed to boost overall efficiency and patient care results. According to Department of Health and Social Care figures cited by officials, the surge in national data opt-outs directly mirrors intense media coverage surrounding the defense contractor’s past work. Doctors and patient advocacy groups are pressing Labour ministers to exercise a contractual break clause immediately.
Critics point to the firm’s prior technology contracts with the Israeli military and Donald Trump’s ICE immigration agency as core reasons for public hesitation. Tom Hegarty, head of communications for the tech equity campaign Foxglove, noted that public concern is entirely justified given comments from Palantir founder Peter Thiel, who previously stated that the NHS makes people sick. While opting out does not block an individual’s records from being used for direct, live operations, it permanently prevents health authorities from utilizing those files for broader medical research and NHS planning.
Did you know? Under the national data opt-out mechanism, patients can choose to stop their confidential health information from being used for research and planning, though it never blocks data needed for direct medical care or live surgeries.
Company Claims Countered by NHS Independence and Statistical Scrutiny
Palantir and its supporters maintain that its artificial intelligence software has successfully cut hospital waiting lists and improved patient throughput. A representative for the firm highlighted that healthcare trusts implementing its software documented 110,000 more procedures, achieved a 15% drop in delayed discharges for patients staying long-term, and saw a 6.8% boost in how quickly 28-day cancer diagnoses were delivered. However, NHS England stated it could not draw definitive conclusions about cause and effect from those operational metrics, and the UK statistics watchdog has launched an investigation into the data.
The controversy extends beyond national health infrastructure. London mayor Sadiq Khan blocked the Metropolitan Police from awarding Palantir a £50m contract to deploy AI investigative tools, asserting that public funds should only support vendors that share local municipal values. Palantir responded by launching legal action against the mayor’s decision. Meanwhile, previous government transparency failures—including an incident where corporate staff gained access to identifiable patient records—have triggered ministerial apologies and heightened ongoing security oversight.
Shifting Government Stance on Mandatory Platform Adoption
Health minister James Frith indicated a notable policy shift regarding whether local health trusts must adopt the Palantir-powered platform. While a health minister told parliament in July that trusts would be mandated to use parts of the federated data platform, Frith clarified in his recent letter that use of the FDP is not mandatory and individual organizations may choose alternative technical solutions. A Department of Health and Social Care spokesperson maintained there has been no change in official policy, insisting the platform was never compulsory.
Liberal Democrat MP Layla Moran welcomed the softened stance on mandatory adoption but urged ministers to take decisive action before February rather than extending the current agreement. “Given how long this process could take, ministers need to act decisively and quickly,” Moran said. Frith warned that despite the rise in opt-outs remaining modest so far, long-term realization of the government’s 10-year health plan remains at risk if public willingness to share data continues to erode.
Frequently Asked Questions
Does opting out affect my regular doctor appointments or live surgery?
No. According to NHS guidelines, opting out only prevents your medical records from being utilized for secondary purposes like health research and NHS planning. It has zero impact on direct patient care, live operations, or routine GP appointments.
Is the NHS federated data platform mandatory for hospitals?
No. The Department of Health and Social Care confirmed that NHS trusts are not required to use the platform and retain the freedom to select alternative technical solutions that meet local healthcare needs.
Why are patients and doctors objecting to Palantir?
Campaign groups, doctors, and patients have raised concerns over the firm’s past work with the Israeli military and US immigration enforcement, alongside controversial statements made by company founder Peter Thiel regarding the UK health service.
What are your thoughts on the use of private tech companies within the NHS? Join the discussion by leaving a comment below, explore our latest health technology coverage, or subscribe to our daily news briefing to receive updates straight to your inbox.
Keep reading